US 11,850,236 B2
Method for inhibiting Zika virus infection
Hengli Tang, Tallahassee, FL (US); Emily M. Lee, Tallahassee, FL (US); Wei Zheng, Rockville, MD (US); Ruili Huang, Rockville, MD (US); Miao Xu, Rockville, MD (US); Wenwei Huang, Rockville, MD (US); Khalida Shamim, Rockville, MD (US); Guoli Ming, Philadelphia, PA (US); and Hongjun Song, Philadelphia, PA (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethseda, MD (US); Florida State University Research Foundation, Inc., Tallahassee, FL (US); and The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC., Tallahassee, FL (US); The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US); and THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Jun. 28, 2022, as Appl. No. 17/809,339.
Application 17/809,339 is a continuation of application No. 16/861,281, filed on Apr. 29, 2020, granted, now 11,471,443.
Application 16/861,281 is a continuation of application No. 16/721,221, filed on Dec. 19, 2019, granted, now 11,096,927, issued on Aug. 24, 2021.
Claims priority of provisional application 62/781,687, filed on Dec. 19, 2018.
Prior Publication US 2022/0362217 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4162 (2006.01); A61P 31/14 (2006.01); A61K 31/4184 (2006.01); A61K 31/245 (2006.01); A61K 31/433 (2006.01); A61K 31/4535 (2006.01); A61K 31/517 (2006.01); A61K 31/4741 (2006.01); A61K 31/554 (2006.01); A61K 31/422 (2006.01); A61K 31/4709 (2006.01); A61K 31/336 (2006.01); A61K 31/427 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/352 (2006.01); A61K 31/165 (2006.01)
CPC A61K 31/4184 (2013.01) [A61K 31/165 (2013.01); A61K 31/245 (2013.01); A61K 31/336 (2013.01); A61K 31/352 (2013.01); A61K 31/4162 (2013.01); A61K 31/422 (2013.01); A61K 31/427 (2013.01); A61K 31/433 (2013.01); A61K 31/4535 (2013.01); A61K 31/4709 (2013.01); A61K 31/4741 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/554 (2013.01); A61P 31/14 (2018.01)] 5 Claims
 
1. A method for inhibiting Zika virus infection in human or non-human mammalian cells in vitro or in vivo, said method comprising contacting a compound to a human or non-human mammalian cell in vitro or in vivo after exposure of the cell to the Zika virus, wherein the compound has the following chemical structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.